-- Presentation to be webcast on www.exelixis.com
--
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 12, 2015--
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s president and chief executive officer, will provide
an overview of the company at Stifel’s 2015 Healthcare Conference,
taking place November 17-18 in New York. The Exelixis presentation is
scheduled for 3:00 PM EST/12:00 PM PST on Tuesday, November 17, 2015.
The presentation will be webcast live and may be accessed via the Event
Calendar page under Investors & Media at www.exelixis.com.
Please connect to the company’s website at least 15 minutes prior to the
presentation to ensure adequate time for any software download that may
be required to listen to the webcast. A replay will also be available at
the same location for 14 days.
About Exelixis
Exelixis, Inc. is a biopharmaceutical company committed to developing
small molecule therapies for the treatment of cancer. Exelixis is
focusing its development and commercialization efforts primarily on
cabozantinib, its wholly owned inhibitor of multiple receptor tyrosine
kinases. Positive results were recently announced for a phase 3 pivotal
trial of cabozantinib in patients with advanced renal cell carcinoma who
received at least one prior VEGF receptor tyrosine kinase inhibitor, and
Exelixis expects to complete regulatory filings in the U.S. and European
Union in late 2015 and early 2016, respectively. Another
Exelixis-discovered compound, COTELLIC™, a selective inhibitor of MEK,
received its first regulatory approvals in Switzerland and the United
States, and is being evaluated by Roche and Genentech (a member of the
Roche Group) in a broad development program under a collaboration with
Exelixis. For more information, please visit the company’s website at www.exelixis.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151112006645/en/
Source: Exelixis, Inc.
Exelixis, Inc.
Investors Contact:
Susan
Hubbard, 650-837-8194
Investor Relations and Corporate
Communications
shubbard@exelixis.com
or
Media
Contact:
For Exelixis, Inc.
Hal Mackins,
415-994-0040
hal@torchcommunications.com